Power your medicine
NBTXR3 is a first-in-class radio-enhancer that could be applicable to most of the solid tumors. This product is currently in clinical development across the globe in seven oncology indications.
NBTXR3 is an aqueous suspension of nanoparticles with a special coating designed to penetrate cancer cells and remain within the tumor.
NBTXR3 nanoparticles are designed to be administered by a single intratumoral injection directly into the tumor before the first radiotherapy session.
NBTXR3 development pipeline (*PharmaEngine clinical trials)
The NBTXR3 nanoparticles are intended to enhance radiotherapy energy within the tumor tissue to improve benefit for patients.
The first positive clinical results enabled Nanobiotix to expand its clinical development. There are several indications in clinical trials: Soft Tissue Sarcoma Phase II/III registration trial, Head & Neck Phase I/II, Liver cancers (Hepatocellular carcinoma and liver metastases) Phase I/II trial, Prostate cancer Phase I/II and by PharmaEngine: Head and Neck cancer Phase I/II and Rectal cancer Phase I/II. These trials are running across EU, US and Asia-Pacific region.
Other potential indications for this product include esophageal cancer, glioblastoma and cervical cancer, etc.